Gentium Srl Stock Price, News & Analysis (OTCMKTS:GENTY)

$56.10 0.00 (0.00 %)
(As of 02/16/2018 04:00 PM ET)
Previous Close$56.10
Today's RangeN/A
52-Week Range$7.26 - $59.25
Average Volume6,528 shs
Market Capitalization$872.64 million
P/E Ratio107.88
Dividend YieldN/A

About Gentium Srl (OTCMKTS:GENTY)

Gentium Srl logoGentium SpA is a biopharmaceutical company focused on the development and manufacture of its product candidate, defibrotide, an investigational drug based on a mixture of single-stranded and double-stranded deoxyribonucleic acid (DNA) extracted from pig intestines. The Company's development of defibrotide has been focused on the treatment and prevention of a disease called hepatic veno-occlusive disease ( VOD), a condition that occurs when veins in the liver are blocked as a result of cancer treatments, such as chemotherapy or radiation, that are administered prior to stem cell transplantation. In February 2014, Jazz Pharmaceuticals PLC acquired the 98% interest in Gentium SpA (Gentium).

Receive GENTY News and Ratings via Email

Sign-up to receive the latest news and ratings for GENTY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E Ratio107.884615384615
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A

Gentium Srl (OTCMKTS:GENTY) Frequently Asked Questions

What is Gentium Srl's stock symbol?

Gentium Srl trades on the OTCMKTS under the ticker symbol "GENTY."

Who are some of Gentium Srl's key competitors?

Who are Gentium Srl's key executives?

Gentium Srl's management team includes the folowing people:

  • Khalid Islam Ph.D., Chairman of the Board, Chief Executive Officer, Interim Scientific Director (Age 61)
  • Salvatore Calabrese, Chief Financial Officer, Chief Operating Officer (Age 44)
  • Carin Heringa, Senior Vice President, Scientific Director (Age 52)
  • Marco Maria Brughera, Director (Age 60)
  • Laura Ferro Ph.D., Director (Age 62)
  • Gigliola Bertoglio CPA, Independent Director (Age 79)
  • Bobby W. Sandage Jr., Ph.D., Independent Director (Age 63)
  • Elmar J. Schnee, Independent Director (Age 57)

How do I buy Gentium Srl stock?

Shares of Gentium Srl can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Gentium Srl's stock price today?

One share of Gentium Srl stock can currently be purchased for approximately $56.10.

How big of a company is Gentium Srl?

Gentium Srl has a market capitalization of $872.64 million.

How can I contact Gentium Srl?

Gentium Srl's mailing address is Piazza XX Settembre, 2, VILLA GUARDIA, 22079, Italy. The biopharmaceutical company can be reached via phone at +39-31-5373200.

MarketBeat Community Rating for Gentium Srl (GENTY)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  66 (Vote Outperform)
Underperform Votes:  32 (Vote Underperform)
Total Votes:  98
MarketBeat's community ratings are surveys of what our community members think about Gentium Srl and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Gentium Srl (OTCMKTS:GENTY) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Gentium Srl (OTCMKTS:GENTY) Earnings History and Estimates Chart

Earnings by Quarter for Gentium Srl (OTCMKTS:GENTY)

Gentium Srl (OTCMKTS GENTY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2013$0.20$0.22$15.75 million$16.19 millionViewListenView Earnings Details
8/13/2013Q2 2013$0.02$0.16$13.49 million$13.62 millionViewN/AView Earnings Details
5/14/2013Q1 2013($0.08)$0.06$8.82 million$10.51 millionViewN/AView Earnings Details
3/28/2013Q4 2012($0.09)$0.05ViewN/AView Earnings Details
11/15/2012Q3 2012($0.06)$0.02ViewN/AView Earnings Details
9/13/2012Q2 2012($0.04)$0.06ViewN/AView Earnings Details
5/17/2012Q1 2012$0.07($0.08)ViewN/AView Earnings Details
3/27/2012Q4 2011$0.04$0.01ViewN/AView Earnings Details
11/15/2011Q3 2011$0.05$0.02ViewN/AView Earnings Details
9/20/2011Q2 2011$0.14$0.08ViewN/AView Earnings Details
5/12/2011Q1 2011$0.14$0.15ViewN/AView Earnings Details
3/28/2011Q4 2010$0.14$0.07ViewN/AView Earnings Details
11/8/2010Q3 2010$0.11ViewN/AView Earnings Details
8/12/2010Q2 2010$0.21ViewN/AView Earnings Details
11/30/2009Q3 2009($0.28)ViewN/AView Earnings Details
9/17/2009Q2 2009($0.44)ViewN/AView Earnings Details
6/4/2009Q1 2009($0.26)ViewN/AView Earnings Details
3/31/2009Q4 2008($0.20)($0.31)ViewN/AView Earnings Details
3/10/2009Q3 2008($0.27)ViewN/AView Earnings Details
12/17/2008Q2 2008($0.47)ViewN/AView Earnings Details
6/26/2008Q1 2008($0.56)($0.64)ViewN/AView Earnings Details
4/1/2008Q4 2007($0.47)($0.53)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Gentium Srl (OTCMKTS:GENTY) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Gentium Srl (OTCMKTS:GENTY)

No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Gentium Srl (OTCMKTS GENTY)

No insider trades for this company have been tracked by


Gentium Srl (OTCMKTS GENTY) News Headlines

No headlines for this company have been tracked by

SEC Filings

Gentium Srl (OTCMKTS:GENTY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Financials are not available for this stock.


Gentium Srl (OTCMKTS GENTY) Stock Chart for Saturday, February, 17, 2018

Loading chart…

This page was last updated on 2/17/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.